# Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

> **NCT07704658** · PHASE4 · RECRUITING · sponsor: **Rigel Pharmaceuticals** · enrollment: 12 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)
- Thyroid Cancer
- Solid Tumor Malignancies
- Advanced Malignancies

## Interventions

- **DRUG:** Pralsetinib
- **DRUG:** CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive

## Key facts

- **NCT ID:** NCT07704658
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704658, "Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*